1. Polymer nanotherapeutics with the controlled release of acetylsalicylic acid and its derivatives inhibiting cyclooxygenase isoforms and reducing the production of pro-inflammatory mediators.
- Author
-
Frejková M, Běhalová K, Rubanová D, De Sanctis JB, Kubala L, Chytil P, Šimonová A, Křížek T, Randárová E, Gunár K, and Etrych T
- Subjects
- Animals, Mice, Drug Liberation, Inflammation Mediators metabolism, Cyclooxygenase Inhibitors pharmacology, Cyclooxygenase Inhibitors administration & dosage, Cyclooxygenase Inhibitors chemistry, Drug Carriers chemistry, Prostaglandin-Endoperoxide Synthases metabolism, Acrylamides chemistry, Acrylamides pharmacology, Acrylamides administration & dosage, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents chemistry, Aspirin administration & dosage, Aspirin pharmacology, Aspirin chemistry, Delayed-Action Preparations, Nanoparticles chemistry, Polymers chemistry, Polymers administration & dosage
- Abstract
The effective treatment of inflammatory diseases, particularly their chronic forms, is a key task of modern medicine. Herein, we report the synthesis and evaluation of biocompatible polymer conjugates based on N-2-(hydroxypropyl)methacrylamide copolymers enabling the controlled release of acetylsalicylic acid (ASA)-based anti-inflammatory drugs under specific stimuli. All polymer nanotherapeutics were proposed as water-soluble drug delivery systems with a hydrodynamic size below 10 nm ensuring suitability for the parenteral application and preventing opsonization by the reticuloendothelial system. The nanotherapeutics bearing an ester-bound ASA exhibited long-term release of the ASA/salicylic acid mixture, while the nanotherapeutics carrying salicylic acid hydrazide (SAH) ensured the selective release of SAH in the acidic inflammatory environment thanks to the pH-sensitive hydrazone bond between the polymer carrier and SAH. The ASA- and SAH-containing nanotherapeutics inhibited both cyclooxygenase isoforms and/or the production of pro-inflammatory mediators. Thanks to their favorable design, they can preferentially accumulate in the inflamed tissue, resulting in reduced side effects and lower dosage, and thus more effective and safer treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF